Reply to Burghes  by MacKenzie, Alex E.
Letters to the Editor 485
parently, the ArC substitution is more common in the
normal Mediterranean population. We had missed this
because of the error in the study by Figus et al. (1995),
as is noted in the letter by Loudianos et al. (1998 [in
this issue]). Promoter studies are currently in progress
to determine the nature of the mutations reported by us.
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Reply to Burghes
To the Editor:
In his recent editorial entitled “When Is a Deletion Not
a Deletion? When It Is Converted” Burghes (1997) cor-
rectly ascribes the cause of spinal muscular atrophy
(SMA) to the loss or mutation of the telomeric copy of
the SMN (survival motor neuron) gene. The reduction
in SMN protein, as Burghes recognizes, most likely leads
to motor-neuron death, by unknown mechanisms
(Coovert et al. 1997; Lefebvre et al. 1997). He also out-
lines the probable role of centromeric copies of SMN in
the modulation of disease severity (Campbell et al. 1997;
Velasco et al. 1996; McAndrew et al. 1997). However,
concerning a second SMA candidate gene, known as
NAIP (neuronal apoptosis–inhibitory protein), Burghes
states that “it appears likely that the deletion of NAIP
marks the extent of the [genomic] deletion and that dif-
ferent forms of SMNcen modify the SMA phenotype,”
thereby rejecting a role for NAIP in SMA pathogenesis.
On this final point we strongly disagree. During the
past 2 years, our group, our collaborators, and other
laboratories have shown that NAIP could be involved
in SMA pathogenesis in several ways. First, in most pop-
ulations the NAIP gene is deleted in the majority of type
I SMA individuals. In some type I SMA populations, the
deletion of SMNtel extends to NAIP in 180% of affected
chromosomes (Morrison 1996; Samilchuk et al. 1996;
Velasco et al. 1996). Second, in the CNS, NAIP is ex-
pressed in at least eight distinct neuronal populations,
including the motor neurons, all of which are affected
in type I SMA (Towfighi et al. 1985; Murayama et al.
1991; Peress et al. 1986; Xu et al. 1997b). A number
of NAIP-positive neuronal types (e.g., cholinergic neu-
rons of the striatum), when subjected to ischemia, dem-
onstrate both a significant increase in NAIP levels (Xu
et al. 1997a) as well as a marked resistance to apoptotic
death. Third, NAIP exerts an antiapoptotic effect in cul-
tured cells (Liston et al. 1996) and affords hippocampal
neuroprotection in vivo when overexpressed from a
transgene (Xu et al. 1997a).
In view of these data, we find the assertion surprising
that the NAIP gene serves merely as a marker of ge-
nomic-DNA deletion size. Clearly, formal proof of NAIP
involvement in SMA pathogenesis must await further
analysis (e.g., exacerbation of an SMA phenotype in
SMN-deficient mice when expression of NAIP is com-
promised). However, we feel that it is likely that motor
neurons from SMA individuals with deletions of both
NAIP and SMNtel are prone to apoptosis. As a result,
the cells are less able to withstand the stress of SMN
depletion and die earlier than they would otherwise, re-
sulting in a more severe form of SMA.
ALEX E. MACKENZIE
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Reply to Mackenzie
To the Editor:
MacKenzie suggests that, in my editorial “When Is a
Deletion Not a Deletion? When It Is Converted”
(Burghes 1997), I have not ascribed sufficient signifi-
cance to the role of the neuronal apoptosis inhibitory
protein (NAIP) gene in spinal muscular atrophy (SMA).
In particular, MacKenzie takes issue with the following
statement: “Further work is required to clearly define
the mechanism by which the converted alleles modify
phenotype, and it is possible that deletion of adjacent
genes, such as NAIP, could influence the exact severity
of the phenotype. However, it appears most likely that
the deletion of NAIP marks the extent of the deletion
and that different forms of SMNC modify the SMA phe-
notype” (Burghes 1997, p. 13).
It is my opinion that this is a fair reflection of our
current knowledge of the situation and that, at present,
there is not adequate evidence to implicate NAIP as a
major SMA-modifying gene. The first and foremost ar-
gument against involvement of NAIP comes from genetic
studies. MacKenzie indicates that, in some type I SMA
populations, the rate of NAIP deletion approaches 80%.
However, in most cases in which a noninbred population
has been studied, the rate of NAIP deletion in type I
SMAs is 45%–50% (Cobben et al. 1995; Hahnen et al.
1995; Roy et al. 1995; Thompson et al. 1995; Velasaco
et al. 1996; DiDonato et al 1997b). MacKenzie states
that “we feel it likely that motor neurons from SMA
individuals with deletions of both NAIP and SMNtel are
prone to apoptosis. As a result, the cells are less able to
withstand the stress of SMN depletion and die earlier
than they would otherwise, resulting in a more severe
form of SMA.” This would predict that the disease in
those patients without a deletion of the NAIP gene
would be mild, whereas the disease in those patients with
a NAIP gene deletion would be severe. Patients with
SMNT intragenic mutations that still retain the NAIP
gene would also be predicted to have a mild form of the
disease. So a critical question is, Do the type I SMA
cases without NAIP deletions show a clinical progression
different from that seen in patients with an NAIP de-
letion? There is no clear difference between these two
populations. In addition, type II/III SMA cases can have
deletions of NAIP, as can carriers with no clinical phe-
notype (Cobben et al. 1995; Hahnen et al. 1995; Roy
et al. 1995; Thompson et al. 1995; Rodrigues et al. 1996;
Campbell et al. 1997; DiDonato et al. 1997b). There-
fore, it does not always seem to be the case that motor
neurons lacking NAIP are more sensitive to the loss of
SMNT. It could be argued that the type I SMA cases
with an intact NAIP gene have another mutation, which
is not detectable by current assays—and that they there-
fore are phenotypically equivalent—whereas type II/III
SMA patients with a deletion of NAIP somehow make
the NAIP protein in the motor neurons. This indicates
two critical studies that are needed to substantiate NAIP
as a major modifier of SMA. First, there must be detec-
tion of intragenic NAIP mutations in the type I SMA
patients who have an intact NAIP gene. Second, there
must be studies at the protein level that show reduction
of the NAIP protein in motor neurons of type I SMA
patients who do not have a deletion of the NAIP gene.
